STOCK TITAN

Synlogic Inc - SYBX STOCK NEWS

Welcome to our dedicated news page for Synlogic (Ticker: SYBX), a resource for investors and traders seeking the latest updates and insights on Synlogic.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Synlogic's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Synlogic's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.33%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.24%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.38%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.81%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
none
Synlogic Inc

Nasdaq:SYBX

SYBX Rankings

SYBX Stock Data

20.85M
2.92M
10.3%
70.47%
0.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About SYBX

at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre